PDCD1 and metastatic melanoma: The lack of an increased survival benefit obtained with the small molecule IDO1 inhibitor epacadostat when combined with the PD1 blocking antibody pembrolizumab in a Phase 3 trial for unresectable or metastatic melanoma (74) was a stark reminder that successful clinical development of an effective cancer drug is hardly a sure thing (75).